ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

New Lung Cancer Research Offers Patients Hope

By: NewsUSA

(NewsUSA) - New research in the treatment of small cell lung cancer offers hope to patients.     

Until recently, small cell lung cancer (SCLC) was considered a forgotten cancer, but now there is a new type of chemotherapy treatment and promising research into targeted therapies that may shrink the tumors of a subset of small cell lung cancer patients.     

Small cell lung cancer (SCLC) is currently only treatable by chemotherapy and immunotherapy, and it is difficult to identify, so most patients are already an in advanced stage of cancer when they are diagnosed. SCLC spreads quickly and is resistant to many treatments; it also comes back more aggressively after treatment. However, researchers have identified a subset of SCLC patients who appear to respond to drugs that are already proven cancer fighters; the proteins in the tumors of these patients make them more receptive to targeted therapies, according to the researchers.   

“The next step in the research is enrolling patients in clinical trials, which are safe and the gold standard of care for SCLC patients,” says Dr. Dwight Owen, a medical oncologist at The Ohio State University.     

Dr. Owen recommends that all adults aged 50 years and older with a history of smoking, or who are current smokers, should be screened for lung cancer. However, “anyone with lungs can have lung cancer,” he emphasized.     

Meanwhile, Dr. Owen encourages anyone with a lung cancer diagnosis to ask their doctor about clinical trials, which are often the best resource for the most advanced treatment.     

“Clinical trial research determines if a promising new treatment, drug or device is safe and effective. For many patients, these trials are the best treatment option and provide new treatments that help them live,” he says.     

Many clinical trials are using telemedicine to “take the trial to the patient” to make clinical trials more accessible to more patients.     

“You should always ask questions to make sure you understand what you will need to do to be part of a clinical trial and make sure you are comfortable,” Dr. Owen explains.     

Be sure to ask your medical team about whether clinical trials could be part of your treatment.     

For more information, visit LCFAmerica.org or text L-C-F-A to 41444.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.17
+3.01 (1.31%)
AAPL  276.67
-0.88 (-0.32%)
AMD  216.26
+2.02 (0.94%)
BAC  53.72
+0.73 (1.38%)
GOOG  318.85
-1.43 (-0.45%)
META  643.91
+10.30 (1.63%)
MSFT  492.26
+6.76 (1.39%)
NVDA  177.96
-2.30 (-1.28%)
ORCL  200.93
-4.03 (-1.97%)
TSLA  431.29
+4.71 (1.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.